The U.S. Supreme Court made a patent-law decision on Monday that could have multibillion-dollar ramifications for patent holders in the biotechnology sector.
The court denied an appeal in Univ. of Rochester v. G.D. Searle & Co.
This effectively solidifies the decision that was made by the U.S. Court of Appeals for the Federal Circuit, which invalidate......Full article >>>
ned to be significant in the production and discovery of non-steroidal and anti-inflammatory drugs.
The University of Rochester ultimately received a patent (6,048,850) which covered methods for selectively inhibiting PGHS-2 activity in a human host, comprising administering a nonsteroidal compound that selectively inhibits activity of the PGHS-2 gene product to a human host in need of su......Full article >>>
In the case of Noelle v. Lederman
, the Federal Circuit decided that a patent for an antibody need not provide a written description of the antibody. However, provided that an application discloses a fully characterized antigen, the application may properly claim an antibody by its binding affinity to that described antigen. At first glance, this may appear to contra......Full article >>>
ication that fulfills the statutory requirements. An inventor may add additional description to the application, but it must then be filed as a separate child application. The problem with this procedure is that the new matter added would have a priority date of the child application and not of the parent.
For biotechnology related inventions a matter of days can translate into considerab......Full article >>>
those of the author, & do not necessarily reflect the views of The Wisconsin Technology Network, LLC. (WTN). WTN, LLC accepts no legal liability or responsibility for any claims made or opinions expressed herein.......Full article >>>
Source:wistechnology.com By Jonathan Fritz 12/01/04Related biology technology :1
. The state of global biotech: An Ernst & Young perspective2
. Olympics of biotechnology has international flavor3
. Getting noticed in Genetown: Wisconsin biotech on display4
. Madison biotech NimbleGen files for IPO; one of states best-funded firms5
. Wisconsin biotech firm receives $107K NIH grant6
. Manufacturing partnership will move into biotech and biomedical spaces7
. Wisconsin wont get Georgia biotech without a fight8
. The 10 biggest events shaping biotech in 20069
. NimbleGen partners with UK biotech firm10
. 2006: A great biotech financing year, unless you were going public!11
. Big pharma seeks Wisconsin biotech partnerships